Menu
Pancreatic cancer
...is the least funded cancer in terms of research. Despite causing enormous mortality, pancreatic cancer receives (on a mortality basis) much less funding for research.
Click Here to Help
Pancreatic cancer
...is the most aggressive of the major cancers, has the highest mortality rate, and the LEAST funded. There are no early detection tests.
Click Here to Help
Pancreatic cancer
Pancreatic cancer has the lowest survival rate of all cancers. This year, an estimated 56,770 adults (29,940 men and 26,830 women) in the United States will be diagnosed.
Click Here to Help
Walk, Run, or Choose your own!
Set up a fundraising page to start now! We will be in touch, and be with you all the way!
Click Here to Start
Previous
Next

CONFRONTING PANCREATIC CANCER

Join us in our effort to fight pancreatic cancer. Donations allow for timely delivery of critical information about pancreatic cancer.

PANCREATIC CANCER PROGNOSIS & SURVIVAL

Each year more than 50,000 people in the United States (and double this number in Europe) are now diagnosed with pancreatic cancer (adenocarcinoma). The prognosis is such that most of these people will have passed by the end of the first year. In the U.S., pancreatic cancer is 9th or 10th most commonly diagnosed cancer (depending on gender), but the fourth leading cause of cancer death in men and women.

The prognosis of pancreatic cancer (adenocarcinoma of the pancreas) is a very tough, though the survival rates have been incrementally improving particularly over the past ten to fifteen years. It is important to realize that each person is individual; each cancer is different. Statistics can only indicate what tends to happen in the aggregate, and not in the case of an individual person.

islandblocks300

The median survival duration from the time of diagnosis until demise is arguably the worst of any of the cancers – certainly of the major cancers. The median survival for untreated advanced pancreatic cancer is about 3 1/2 months; with good treatment this increases to about eight months, though many will live much longer. We have encountered nine and eleven and twelve  year survivors.

Perhaps it is a good place to discuss what the term median means. Simply put, the median is the time point that separates half of patients who live longer from the half who will live less. Thus, there are many patients who will live much longer than the median.

The American Cancer Society prognosis figures show that the stage at which pancreatic cancer is diagnosed is strongly correlated to survival; earlier obviously being better. But, the statistics are still pretty tough. The five year survival rate with good treatment is now considered to be about 8%.  Again, it is imperative to understand that each person’s situation individual; each cancer is different. Statistics can only indicate what tends to happen in the aggregate, and not in the case of an individual person. Many people do better than average.

islandblocks300

The prognosis for those who are able to have surgery is improved over those who are not able. Unfortunately, only about 15% of those individuals with pancreatic cancer will be found to be eligible for surgery – for most, the cancer will have been found to be too advanced. For example, patients with pancreatic cancer who received the Whipple surgical procedure in one study (from a very experienced Johns Hopkins team) were reported as having a 21% five-year survival rate, with a median survival of 15.5 months. In more recent studies this five-year median survival duration after surgery has been reported as high as twenty months.

The prognosis is also better for those whose pancreatic cancer is diagnosed at an earlier stage. The median survival duration from diagnosis with chemotherapy medical treatment in locally advanced cancer of the pancreas has been reported as 6 to 12 months.

Patients with neuroendocrine tumors tend to have a much more favorable prognosis than, for example, those with adenocarcinoma of the pancreas. The natural history of neuroendocrine tumors, islet cell tumors, and carcinoid tumors tends to be very different than that of pancreatic adenocarcinoma. For example, the median survival duration from the time of diagnosis for patients with non-functioning metastatic islet cell tumors approaches five years.

ABSTRACTS:

The following are descriptions of titles of abstracts of medical journal articles that may be interesting or useful to those who are interested in further information about this topic. These abstracts can be searched Here.

  • 1-Oct-16 – Prognostic factors for those treated with Gemzar 
  • 1-Oct-16 – Prognosis schema for advanced pancreatic cancer 
  • 28-Jul-16 – Standard factors for prognosis in pancreatic cancer surgery 
  • 1-Jul-15 – mRNAs for prognosis of cancer of the pancreas 
  • 1-Nov-13 – Long Duration Survivors with Cancer of the Pancreas  – Are they There?
  • 1-Jan-13 – Prognosis of Early Stage Cancer of the Pancreas
  • 1-Jun-12 – Prognostic Advantage of Ajduvant Treatment of Pancreatic Adenocarcinoma
  • 1-Jun-12 – Resection and Prognosis of Pancreatic Tumors
  • 1-Mar-12 – Treatment and Prognosis of Cancer of the Pancreas
  • 1-Mar-12 – Prognosis of Pancreatic Cancer – the Chemoradiotherapy Controversy
  • 28-Feb-12 – Gemcitabine vs. FOLFIRINOX Regimens: Prognosis
  • 1-Feb-12 – Chemoradiation Plus Induction Chemo for Locally Advanced Cancer of the Pancreas
  • 1-Dec-11 – Survival Statistics for Neoadjuvant Therapy
  • 1-Nov-11 – Prognosis of IPMN
  • 1-Jul-11 – The Promise of FOLFIRINOX: Improved prognosis
  • 1-May-11 – Better Prognosis: 5-FU Combination Therapy

 

Join the fight against pancreatic cancer!

Set up a fundraising page to join the fight! We will be in touch, and be with you all the way!

Our science board is composed of:

James Abbruzzese, MD Chief, Medical Oncology Duke University

Markus Büchler, MD Chairman, Surgery Heidelberg University, Germany

Ralph Hruban, MD Director, GI / Liver Pathology Johns Hopkins University

Eileen O’Reilly, MD Associate Director for Clinical Research – Memorial Sloan-Kettering Cancer Center

Margaret Tempero, MD Chief, Medical Oncology University of California at San Francisco


 

Walk, Run, or Choose your own!

Set up a fundraising page to join the fight against pancreatic cancer. We will be in touch, and be with you all the way!

Sign up for the latest news about pancreatic cancer, ways to help, and more!

You have likely found us either because you have pancreatic cancer, or care about someone who does.

Our Philosophy About Pancreatic Cancer


Pancreatic cancer is a serious disease. Taking an aggressive rational stance at the earliest possible time, supported by the best medical team, and treated in the most appropriate manner gives the best chance for survival.

We believe in strong patient-physician bonds, scientifically-based treatment, and that comfort can come from knowing that everything that reasonably can be done – is being done.

That the best approach is meeting cancer of the pancreas head-on and armed with the best available information.

Genetic Testing for Pancreatic Cancer

PROPOSED: Every newly diagnosed person with pancreatic cancer (ductal adenocarcinoma of the pancreas) should receive genetic screening prior to beginning treatment – to test for germline genetic mutations in the homologous recombination DNA repair pathway, including genes such as BRCA1, BRCA2, PALB2, and others. These results, in from 12% to 17% of pancreatic cancer patients, suggest that treatment that includes DNA cross-linking agents such as platinum compounds or PARP inhibitors may be superior to standard best practices therapy.


OFFER: Color Genomics offers a 30-gene cancer panel for $224 (normally $249) when the Promotion Code “PANCREATIC” is entered at checkout (price will reduce upon entering this code). This is a physician-ordered saliva kit. Click Here for more information

RATIONALE: The age of precision medicine in pancreatic cancer is approaching … [MORE]

Check out the Suzanne Wright Foundation

CodePurpleNow is their campaign inspired by Suzanne Wright and her fight against pancreatic cancer. During her lifetime, Suzanne dedicated herself to the most vulnerable among us. After her diagnosis, she made it her mission to fight pancreatic cancer with that same determination. More Here

Speak with a Survivor:

Call 1-800-433-0464 for a free service that will place you in contact with a fellow survivor, or to volunteer to contact someone more recently diagnosed.


Pancreatic Cancer Blog

One of the observations that physicians often made when the standard of care treatment typically consisted of the chemotherapy drug agent of gemcitabine alone, was that many patients with pancreatic cancer (ductal adenocarcinoma of the pancreas) seemed to feel better after the initiation of treatment… More Here

 

Best of the Blog

© 2019 Pancreatica. All rights reserved | Privacy Policy
312 Fountain Avenue, Pacific Grove, California 93950   |   Phone: (831) 658-0600   |   Fax: (831) 658-0518  |  participate@tofightcancer.com

MAKE AN IMPACT

Pancreatic cancer is expected to become the 2nd leading cause of cancer-related death by the year 2020

Make a tax-deductible Donation

TOGETHER WE CAN MAKE A DIFFERENCE !